United States: Capitol Hill Healthcare Update - September 25, 2017

GOP Divisions Threaten to Sink ACA Repeal Effort – Again

Republicans' last-ditch effort to overhaul the Affordable Care Act (ACA) suffered potentially fatal blows as GOP senators in recent days voiced either outright opposition to or serious reservations about legislation pushed by Sens. Lindsey Graham (R-S.C.) and Bill Cassidy (R-La.).

The senators' bill would repeal the ACA's individual and employer mandate penalties and turn the law's Medicaid expansion into a trillion-dollar block grant to states. Graham and Cassidy also were readying last-minute funding and regulatory changes in an effort to woo reluctant Republican colleagues in advance of today's Senate Finance Committee hearing on the legislation.

Republicans plan to begin Senate floor debate on the bill Wednesday with a key procedural vote. It is not clear whether today's changes to Graham-Cassidy are sufficient to win over at least 50 Republicans for that test vote and later to pass the bill. Without a clear path forward, Senate Majority Leader McConnell has said he does not want his party to go through an excruciating exercise like July's one-vote failure to advance a different version of ACA replace legislation.

To date there have been no indications even one Democrat – such as Sen. Joe Manchin (D-W.V.) – would break with their party and back Graham-Cassidy. Republicans hold 52 Senate seats, so if more than two GOP senators defect, the legislation would fail.

Sen. Rand Paul (R-Ky.) earlier said he could not support Graham-Cassidy because it keeps most of the ACA's spending and taxes in place even as it shifts decision-making to the states. Because those block grants are at the heart of Graham-Cassidy, it is doubtful legislative accommodations could be made to win Paul's support. Still, Senate leaders and the White House were hopeful to persuade Paul with other provisions.

Sen. John McCain (R-Ariz.) on Friday announced his opposition to the bill, despite the strong backing of Arizona's Republican governor and McCain's long-standing friendship with Graham. McCain's no vote brought down Republicans' last effort to overhaul the ACA in July.

Sen. Susan Collins (R-Maine) has expressed "strong reservations" about Graham-Cassidy, including its redistribution of Medicaid funding from states that expanded their programs under the ACA as well as blocking Planned Parenthood from receiving federal reimbursements. Collins has not definitively said she is voting against the bill, but most GOP leadership staff believe she will not support it.

Sen. Lisa Murkowski (R-Alaska) also said she is concerned about Medicaid and Planned Parenthood. Alaska's independent governor has come out against Graham-Cassidy. Like Collins, Murkowski has not yet said how she would vote.

Complicating an already daunting task for Republican leaders, Sen. Ted Cruz (R-Texas) said Sunday he could not support the bill in its current form – despite Texas seeing a significant increase in Medicaid spending and regulatory flexibility under Graham-Cassidy. Some Senate Republicans believe Cruz is withholding his vote in order to gain concessions but that he would ultimately support the bill.

Republicans face a Saturday deadline to use the fast-track reconciliation procedures that allow them to pass the legislation on a party-line vote. After September 30, Republicans would need 60 votes to block a Democrat filibuster.

Do Republicans Turn Back to ACA Stabilization Efforts?

Senate HELP Committee Chairman Lamar Alexander (R-Tenn.) last week stopped bipartisan talks on shoring up the ACA's individual markets, while Republican leaders focused on a final effort to repeal the ACA.

But with ACA overhaul legislation backed by Sens. Lindsey Graham (R-S.C.) and Bill Cassidy (R-La.) possibly dead, Alexander is expected to try to revive efforts with top committee Democrat Patty Murray (D-Wash.). The senators had been working on ways to stabilize insurance premiums in the ACA's individual markets.

The outlines of the agreement would extend the healthcare law's cost-sharing reduction payments to insurers to subsidize coverage premiums for individuals while also providing states with increased flexibility to approve low-cost insurance plans.

Those waiver details, however, have not been settled and likely represent the biggest threat to an agreement. Republicans want to give states broad flexibility to bring down rates mostly by relaxing coverage requirements, but Democrats warn they will not back waivers that undermine the ACA's consumer protections and coverage mandates.

House Republicans Seek Answers From Merck on Cyber Attack

Leaders on the House Energy and Commerce Committee last week sought information from Merck and the U.S. Department of Health & Human Services (HHS) on a malware attack that struck the company last summer and continues to affect its drug supply.

Energy and Commerce Committee Chairman Greg Walden (R-Ore.) and Rep. Tim Murphy (R-Pa.), the panel's Oversight and Investigations Subcommittee chairman, wrote letters to Merck CEO Ken Frazier and HHS Secretary Tom Price.

While the Merck malware attack has been known about for several months, the company only recently said the attack continues to affect its operations. Walden and Murphy said they wanted to understand more about the event and its ongoing consequences to determine whether the committee should consider a legislative response to protect the healthcare sector from future cyber threats.

Although only Republicans signed the letters, the committee did conduct a bipartisan inquiry last year into cyber vulnerabilities for medical devices, particularly devices connected to the Internet.

Meanwhile, on Wednesday the House Oversight and Government Reform Committee will hold a hearing on cyber threats to the Internet of Things. Witnesses are expected to discuss cyber risks for medical devices.

Medicare 'Extenders' to Be Added to FAA, Flood Bill

Several Medicare programs scheduled to expire this month are expected to be included in House legislation introduced this week that would reauthorize separate transportation and flood insurance programs.

The Medicare "extenders" include an intravenous immune globulin pilot project, a teaching health center graduate medical education program and a diabetes program for Native Americans. Those programs would be added to legislation renewing the Federal Aviation Administration through next spring.

The intravenous immune globulin pilot project, which would be reauthorized through 2020, treats individuals with lupus and weakened immune systems. Under the $45 million project, Medicare covers services to administer intravenous immune globulin to up to 4,000 patients in their homes.

To offset costs for the programs, the bill would cut $50 million from the Medicare Improvement Fund's $270 million budget beginning in fiscal 2021. That fund aims to facilitate improvements to Medicare hospital coverage under Part A and physicians' services under Part B.

Senior HHS Officials to Testify at Senate Opioid Hearing

Four top HHS officials will testify next week during a Senate HELP Committee hearing about the federal government's response to the opioid crisis.

The committee also will review implementation of last year's Comprehensive Addiction and Recovery Act, which authorizes $181 million to support opioid prevention and treatment programs. The panel will discuss implementation of the 21st Century Cures Act, which included $1 billion in grants to states to combat opioid abuse.

Scheduled witnesses at the October 5 hearing include Food and Drug Administration (FDA) Commissioner Scott Gottlieb, National Institutes of Health (NIH) Director Francis Collins, Centers for Disease Control and Prevention (CDC) Director Brenda Fitzgerald and Elinore McCance-Katz, an assistant secretary at the Substance Abuse and Mental Health Services Administration.

Hatch Calls on CMS to Slow Changes to Home Healthcare

The chairman of the Senate Finance Committee last week said the Centers for Medicare & Medicaid Services (CMS) should exercise "more robust data analysis" when updating a proposed rule that would change how and when Medicare reimburses for home health services.

In a letter to CMS Administrator Seema Verma, Sen. Orrin Hatch (R-Utah) said "CMS may be rushing to finalize complex policy changes too quickly" in the 2018 Home Health Prospective Payment System proposed rule.

CMS proposed new payment models and other changes that differed from recent Medicare Payment Advisory Commission recommendations. Hatch called on Verma to "refrain from finalizing" the proposed rule and to provide stakeholders time to fully analyze potential changes and provide substantive input.

Panel May Hold Hearing on 'Right-To-Try' Legislation

The House Energy and Commerce Health Subcommittee may hold a hearing next week on legislation that would give terminally-ill patients wider access to prescription drugs that haven't yet won FDA approval.

It is not clear whether the subcommittee would hold a hearing on House legislation introduced earlier this year by Rep. Andy Biggs (R-Ariz.) or legislation by Sen. Ron Johnson (R-Wis.) that won Senate approval last month. Johnson's bill would apply only to prescription drugs; the House bill would apply to drugs and medical devices.

Vice President Pence earlier this year endorsed the right-to-try legislation. Pharmaceutical manufacturers have resisted the legislation, saying early access to unapproved drugs could give patients false hope and threaten the integrity of ongoing clinical trials if those patients have adverse reactions.

Grassley: CMS Should Make Hospital Inspection Reports Public

The chairman of the Senate Judiciary Committee is calling on a CMS accrediting agency to publicly release hospital inspection reports.

In a letter to CMS's Administrator Seema Verma, Sen. Chuck Grassley (R-Iowa) wrote that making reports public would help patients decide where to seek care.

Grassley said the Joint Commission also appears to be failing to hold accountable facilities that have not properly cared for patients. He said there are more than 30 instances of hospitals retaining full accreditation even as CMS deemed their violations to be so significant they caused or were likely to cause a risk of serious injury or death to patients.

The senator asked CMS to respond to a series of questions about the inspections reports by October 3.

Lawmakers Question Price's Use of Private Jets

Following news reports that HHS spent more than $400,000 on private jet travel in recent months for Secretary Tom Price, House Democrats are calling for congressional oversight hearings.

HHS announced it would halt Price's private travel while reviews – including by HHS's inspector general – are underway. The department did not explain why the secretary needed to use private jets for 24 trips since early May, according to media reports.

Rep. Elijah Cummings (D-Md.), the top Democrat on the House Oversight and Government Reform Committee, called on panel leaders to examine Price's use of private travel for official business.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
BakerHostetler
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
BakerHostetler
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions